Effects of angiotensin I-converting enzyme inhibitor and angiotensin II type 1 receptor blocker on the right ventricular sarcoglycans and dystrophin after left coronary artery ligation

European Journal of Pharmacology

Volumn 522, Issue 1-3, 2005, Pages 84-93

  Takahashi, Masaya ^a   Tanonaka, Kouichi ^a   Yoshida, Hiroyuki ^a   Koshimizu, Miki ^a   Oikawa, Ryo ^a   Daicho, Takuya ^a   Takeo, Satoshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Angiotensin I converting enzyme inhibitor; Angiotensin II type 1 receptor blocker; Calpain; Dystrophin glycoprotein complex; Hypertrophy; Myocardial infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CASEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; SARCOGLYCAN; TRANDOLAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY LIGATION; CORONARY HEMODYNAMICS; CYTOSOLIC FRACTION; DRUG EFFECT; HEART FAILURE; HEART INFARCTION; HYPERTROPHY; LEFT CORONARY ARTERY; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; TIME SERIES ANALYSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; BLOTTING, WESTERN; BODY WEIGHT; CALCIUM-BINDING PROTEINS; CALPAIN; CORONARY VESSELS; CYTOSOL; DYSTROPHIN; GENE EXPRESSION; HEART RATE; HEART VENTRICLES; INDOLES; LIGATION; MALE; MYOCARDIAL INFARCTION; PROTEIN ISOFORMS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOGLYCANS; TETRAZOLES; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 26844529226     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.08.031     Document Type: Article

References (25)

1. C. Badorff, G.-H. Lee, B.J. Lamphear, M.E. Martone, K.P. Campbell, R.E. Rhoads, and K.U. Knowlton Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy Nat. Med. 5 1999 320 326
2. J.M. Capasso, P. Li, L.G. Meggs, M.V. Herman, and P. Anversa Efficacy of angiotensin-converting enzyme inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats J. Cardiovasc. Pharmacol. 23 1994 584 593
3. M.C. Daniels, R.S. Keller, and P.P. de Tombe Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction Am. J. Physiol., Heart Circ. Physiol. 281 2001 H2150 H2158
4. J. Feng, J. Yan, C.H. Buzin, J.A. Towbin, and S.S. Sommer Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy Mol. Genet. Metab. 77 2002 119 126
5. H. Hanada, T. Yoshida, Y. Pan, Y. Iwata, M. Nishimura, and M. Shigekawa mRNA expression and cDNA sequences of β- and γ-sarcoglycans are normal in cardiomyopathic hamster heart Biol. Pharm. Bull. 20 1997 134 137
6. E.M. Hoogerwaard, E. Bakker, P.F. Ippel, J.C. Oosterwijk, D.F. Majoor-Krakauer, N.J. Leschot, A.J. Van Essen, H.G. Brunner, P.A. van der Wouw, A.A. Wilde, and M. de Visser Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carries in the Netherlands: a cohort study Lancet 353 1999 2116 2119
7. L.M. Kunkel Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy Nature 11 1986 73 77
8. R.S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R.J. Burns, J. Probstfield, R.T. Tsuyuki, M. White, J. Rouleau, R. Latini, A. Maggioni, J. Young, and J. Pougue Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators Circulation 100 1997 1056 1064
9. K.K. McMahon Developmental changes of the G proteins-muscarinic cholinergic receptor interactions in rat heart J. Pharmacol. Exp. Ther. 251 1989 372 377
10. P. Melacini, M. Fanin, D.J. Duggan, M.P. Freda, A. Berardinelli, G.A. Danieli, A. Barchitta, E.P. Hoffman, S. Dalla Volta, and C. Angelini Heart involvement in muscular dystrophies due to sarcoglycan gene mutations Muscle Nerve 22 1999 473 479
11. S. Noguchi, E. Wakabayashi, M. Imamura, M. Yoshida, and E. Ozawa Developmental expression of sarcoglycan gene products in cultured myocytes Biochem. Biophys. Res. Commun. 262 1999 88 93
12. E. Ozawa, S. Noguchi, Y. Mizuno, Y. Hagiwara, and M. Yoshida From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy Muscle Nerve 21 1998 421 438
13. J.M. Pfeffer, M.A. Pfeffer, and E. Braunwald Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure Circulation 75 1987 I149 I155
14. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr., T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker, M. Klein, G.A. Lamas, M. Packer, J. Rouleau, J.L. Rouleau, J. Rutherford, J.H. Wertheimer, and C.M. Hawkins Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators N. Engl. J. Med. 327 1992 669 677
15. A. Sanbe, K. Tanonaka, Y. Hanaoka, T. Katoh, and S. Takeo Regional energy metabolism of failing heart following myocardial infarction J. Mol. Cell. Cardiol. 25 1993 995 1013
16. A. Sanbe, K. Tanonaka, R. Kobayashi, and S. Takeo Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction J. Mol. Cell. Cardiol. 27 1995 2209 2222
17. S. Sandmann, M. Yu, and T. Unger Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction-effects of AT1 and AT2 receptor antagonists and ACE inhibitor Br. J. Pharmacol. 132 2001 767 777
18. S. Sandmann, F. Prenzel, L. Shaw, R. Schauer, and T. Unger Activity profile of calpains I and II in chronically infarcted rat myocardium- influence of the calpain inhibitor CAL 9961 Br. J. Pharmacol. 135 2002 1951 1958
19. C.S. Sweet, C.T. Ludden, I.I. Stabilito, S.E. Emmert, and J.F. Heyse Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction Eur. J. Pharmacol. 147 1988 29 37
20. M. Takahashi, K. Tanonaka, H. Yoshida, R. Oikawa, M. Koshimizu, T. Daicho, T. Toyo-oka, and S. Takeo Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart Cardiovasc. Res. 65 2005 356 365
21. K. Tanonaka, W. Toga, H. Yoshida, K. Furuhama, and S. Takeo Effect of long-term treatment with trandolapril on Hsp72 and Hsp73 induction of the failing heart following myocardial infarction Br. J. Pharmacol. 134 2001 969 976
22. M. Vatta, S.J. Stetson, A. Perez-Verdia, M.L. Entman, G.P. Noon, G. Torre-Amione, N.E. Bowles, and J.A. Towbin Molecular remodeling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy Lancet 359 2002 936 941
23. H. Yoshida, M. Takahashi, K. Tanonaka, T. Maki, Y. Nasa, and S. Takeo Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure Br. J. Pharmacol. 134 2001 150 160
24. H. Yoshida, K. Tanonaka, Y. Miyamoto, T. Abe, M. Takahashi, M.B. Anand-Srivastava, and S. Takeo Characterization of cardiac myocyte and tissue β-adrenergic signal transduction in rats with heart failure Cardiovasc. Res. 50 2001 34 45
25. H. Yoshida, M. Takahashi, M. Koshimizu, K. Tanonaka, R. Oikawa, T. Toyo-oka, and S. Takeo Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction Cardiovasc. Res. 59 2003 419 427